Sentencia Kareda v Benkö: ¿continuidad interpretativa (en materia de competencia judicial internacional respecto a acciones de repetición entre codeudores) o exceso de coherencia jurisprudencial por parte del TJUE?

In its ruling in Kareda v Benkö, the Court of Justice of the European Union reasserts certain interpretative criteria that tend to run constantly through its case-law on international jurisdiction on contractual matters. However, by doing so, the ECJ sacrifices the principle of “close connection between the court and the action”, which, in theory, should play a significant role in that field

Efectos de la suplementación con microminerales en indicadores de producción y su residualidad en sangre, heces y orina de alpacas (Lama lama) en pastoreo.

Con el objetivo de analizar el efecto del nivel de suplemento de microminerales adicionales a la dieta sobre las variables alzada peso y diámetro de la fibra de alpacas, se evaluó la aplicación de tres dosis de selenio y zinc (0,0; 1,0 y 1,5 cc), bajo un (DCA) en arreglo factorial (3 x 2) + (3 x 2). Los resultados mostraron diferencias estadísticas para tratamientos: dosis de selenio, edades, dosis de zinc, edades y para la interacción zinc por edades (Se1E2 con 74,33 kg a los 90 días para alzada a la cruz, Zn1E2 con un promedio de 91,33 cm). La longitud de la fibra los tratamientos Se1E1 y Se1E2 con promedio de 3 cm. Para el diámetro de la fibra los tratamientos 1 (Se0E1) y tratamiento Se1E1 del grupo 1 y los tratamientos Zn0E2 y Zn1E1 del grupo 2 mostraron mejor calidad de la fibra (P < 0,05), con promedios de 28 micras. Se confirmó un efecto beneficioso en el peso vivo, calidad de la fibra en animales maduros de la suplementación con los microelementos Se y Zn, que mejoró las características fenotípicas de producción como el peso vivo, aunque manifestó residualidad en la orina de los animales de 3 a 5 años de edad.Effects of Supplementation with Microminerals on Production Indicators and Blood, Feces, and Urine Traces of Grazing alpaca (Lama lama) ABSTRACTIn this area was applied three doses of selenium and zinc (0.0; 1.0 and 1.5 cc), under a (DCA) in factorial arrangement (3 x 2) + (3 x 2) in order to analyze the effect of the level of additional mineral supplement micro (Selenium, Zinc) to the diet on the raised variables, weight and fiber diameter of alpacas. Results revealed statistical differences for treatment: selenium doses, age, Zinc doses, Zinc interaction for ages. For this, the treatment 4 (Se1E2) with 74.33 kg to 90 days to cross height (Zn1E2) with 91.33 cm average. The length fiber into treatments 3 (Se1E1) and 4 (Se1E2) with 3 cm average. For fiber diameter on treatments 1 (Se0E1) Treatment 3 (Se1E1) of group 1, treatments 8 (Zn0E2) and 9 (Zn1E1) which group 2 charged better fiber quality with 28 microns average. It was confirmed an beneficial effect on live weight and fiber quality in mature animals for mineral supply with Se and Zn con los microelements, that improved the production phenotypical characteristics like weight, but it was manifested minerals urine residuality in 3-5 years old animals

Root architecture governs plasticity in response to drought

Aims: Root characteristics are important for predicting plant and ecosystem responses to resource scarcity. Simple, categorical traits for roots could be broadly applied to ecosystem function and restoration experiments, but they need to be evaluated for their role and behaviour under various stresses, including water limitation. We hypothesised that more complex root architectures allow more plastic responses to limited water than do tap roots. Methods: We carried out two greenhouse experiments: one with a range of grassland plant species; the other with only species of Asteraceae to test the responsiveness of root architectural classes to location of limited water in the soil column. Using trait screening techniques and X-ray tomography, we measured the plasticity of the roots in response to water location. Results: Plasticity of root biomass was lowest in tap rooted species, while fibrous and rhizomatous roots allocated biomass preferentially to where the soil was wettest. X-ray tomography indicated that root morphology was least plastic in rhizomatous species. Conclusions: Our results provide a starting point to effective categorisation of plants in terms of rooting architecture that could aid in understanding drought tolerance of grassland species. They also demonstrate the utility of X-ray tomography in root analyses

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Brane effective actions, kappa-symmetry and applications

This is a review on brane effective actions, their symmetries and some of their applications. Its first part covers the Green–Schwarz formulation of single M- and D-brane effective actions focusing on kinematical aspects: the identification of their degrees of freedom, the importance of world volume diffeomorphisms and kappa symmetry to achieve manifest spacetime covariance and supersymmetry, and the explicit construction of such actions in arbitrary on-shell supergravity backgrounds. Its second part deals with applications. First, the use of kappa symmetry to determine supersymmetric world volume solitons. This includes their explicit construction in flat and curved backgrounds, their interpretation as Bogomol’nyi–Prasad–Sommerfield (BPS) states carrying (topological) charges in the supersymmetry algebra and the connection between supersymmetry and Hamiltonian BPS bounds. When available, I emphasise the use of these solitons as constituents in microscopic models of black holes. Second, the use of probe approximations to infer about the non-trivial dynamics of strongly-coupled gauge theories using the anti de Sitter/conformal field theory (AdS/CFT) correspondence. This includes expectation values of Wilson loop operators, spectrum information and the general use of D-brane probes to approximate the dynamics of systems with small number of degrees of freedom interacting with larger systems allowing a dual gravitational description. Its final part briefly discusses effective actions for N D-branes and M2-branes. This includes both Super-Yang-Mills theories, their higher-order corrections and partial results in covariantising these couplings to curved backgrounds, and the more recent supersymmetric Chern–Simons matter theories describing M2-branes using field theory, brane constructions and 3-algebra considerations

Ten millennia of hepatitis B virus evolution

Hepatitis B virus (HBV) has been infecting humans for millennia and remains a global health problem, but its past diversity and dispersal routes are largely unknown. We generated HBV genomic data from 137 Eurasians and Native Americans dated between ~10,500 and ~400 years ago. We date the most recent common ancestor of all HBV lineages to between ~20,000 and 12,000 years ago, with the virus present in European and South American hunter-gatherers during the early Holocene. After the European Neolithic transition, Mesolithic HBV strains were replaced by a lineage likely disseminated by early farmers that prevailed throughout western Eurasia for ~4000 years, declining around the end of the 2nd millennium BCE. The only remnant of this prehistoric HBV diversity is the rare genotype G, which appears to have reemerged during the HIV pandemic